查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
乾癬：KOL 見解
年間契約型資訊服務
商品編碼
1549555

乾癬：KOL 見解

Psoriasis - KOL Insight
出版日期: 年間契約型資訊服務 | 出版商: FirstWord Group | 英文

價格
簡介目錄

牛皮癬最有效的治療方法是什麼？目前的治療方法與研發的治療方法在療效、安全性和成本效益方面如何？ 據知名 KOL 表示，Bimzelx（bimekizumab）因其高效且副作用可控而成為處方最多的抗 IL17 藥物。 Skyrizi（risankizumab）是抗 IL23 類別的領導者，Tremfya（guselkumab）也因其成本效益而受到歡迎。強生公司的口服藥物 JNJ 77242113 顯示出與 Otezla（apremilast）和 Sotyktu（deucravacitinib）等現有治療藥物競爭的巨大潛力。本報告透過專家意見和詳細分析討論了當前和未來的乾癬治療範例。

本報告調查的主要品牌

  • Humira
  • Enbrel
  • Remicade
  • Cimzia
  • Cosentyx
  • Taltz
  • Siliq/Kyntheum
  • Stelara
  • Tremfya
  • Ilumya/Ilumetri
  • Skyrizi
  • Otezla
  • Bimzelx
  • Sotyktu
  • piclidenoson
  • zasocitinib
  • JNJ 77242113

本報告回答的主要問題

  • 目前的乾癬治療方法在療效、耐受性和易於給藥方面如何使用和評估？與管道中的選項相比如何？
  • 哪些藥物類別（抗 TNF 藥物、抗 IL-12/23 藥物、抗 IL-23 藥物、抗 IL-17 藥物、口服藥物）最有可能影響處方趨勢？
  • 生物相似藥的推出以及目前批准的、新批准的和研發的藥物的使用將在患者人口統計、治療系列和適口性方面影響乾癬治療模式，是否會產生類似的影響？
  • 是否有任何有前途的管道產品？
  • 哪些臨床試驗可能會影響處方趨勢，其結果將如何影響未來的乾癬治療？
  • 未來乾癬的治療狀況將如何依患者細分和治療狀況變化？
  • KOL 對牛皮癬市場的需求和期望是什麼？

目錄

執行摘要

研究目的

抗TNF藥物

  • Humira (adalimumab; AbbVie), Remicade (infliximab; Merck & Co./Johnson & Johnson Innovative Medicine), Enbrel (etanercept; Amgen), Cimzia (certolizumab; UCB)

抗IL17藥物

  • Cosentyx (secukinumab; Novartis)
  • Taltz (ixekizumab; Lilly)
  • Siliq (US)/Kyntheum (EU)brodalumab; Ortho Dermatologics/LEO Pharma)
  • Bimzelx (bimekizumab; UCB)

抗IL12/23藥物

  • Stelara (ustekinumab; Johnson & Johnson Innovative Medicine)

抗IL23藥物

  • Tremfya (guselkumab; Johnson & Johnson Innovative Medicine)
  • Ilumya/Ilumetri (tildrakizumab; Sun Pharma/Almirall)
  • Skyrizi (risankizumab; AbbVie)

PDE IV 拮抗劑

  • Otezla (apremilast; Amgen)

酪胺酸激酶 2 抑制劑

  • Sotyktu (deucravacitinib; Bristol Myers Squibb)

在研藥物

  • Piclidenoson (Can-Fite BioPharma)
  • Zasocitinib (TAK 279; Takeda)
  • JNJ 77242113 (Johnson & Johnson Innovative Medicine)

乾癬治療的未來前景和治療趨勢

  • 主要見解摘要
    • Risankizumab、guselkumab 和 bimekizumab 在乾癬治療範式中與其他藥物具有很強的競爭性；生物仿製藥允許生物製劑進行早期干預。

附錄

KOL突發新聞

簡介目錄

What are the most effective treatments for psoriasis? How do current and pipeline therapies compare in terms of efficacy, safety, and cost-effectiveness? Leading KOLs evaluate Bimzelx (bimekizumab) as the most prescribed anti-IL17 due to its high efficacy and manageable side effects. Skyrizi (risankizumab) is identified as the leader in the anti-IL23 category, with Tremfya (guselkumab) also gaining traction for its cost-effectiveness. Johnson & Johnson's oral drug JNJ 77242113 shows significant potential to compete with existing treatments like Otezla (apremilast) and Sotyktu (deucravacitinib). Gain valuable insights into the current and future treatment paradigms for psoriasis, informed by expert opinions and detailed analysis.

Key brands covered in this report:

  • Humira
  • Enbrel
  • Remicade
  • Cimzia
  • Cosentyx
  • Taltz
  • Siliq/Kyntheum
  • Stelara
  • Tremfya
  • Ilumya/Ilumetri
  • Skyrizi
  • Otezla
  • Bimzelx
  • Sotyktu
  • piclidenoson
  • zasocitinib
  • JNJ 77242113

Key questions answered:

  • How are current therapies for psoriasis used and perceived in terms of efficacy, tolerability, and ease of administration? How do they compare with pipeline options?
  • Which drug class (anti-TNFs, anti-IL-12/23s, anti-IL-23s, anti-IL-17s and oral therapies) has the greatest potential to impact prescribing trends?
  • How will the launch of biosimilars and the use of current, as well as newly approved/pipeline drugs, impact the psoriasis treatment paradigm in terms of patient segment, line of therapy, and preference?
  • Are there any promising pipeline products and if so, how will they impact the current players in the market?
  • Which clinical trials have the potential to impact prescribing trends, and how will the results affect the future treatment of psoriasis?
  • How will the treatment landscape for psoriasis evolve in the future for each patient segment and line of therapy?
  • What are KOLs' demands and expectations from the psoriasis market?

Table of Contents

Executive Summary

Research Objectives

Anti-TNF drugs

  • Humira (adalimumab; AbbVie), Remicade (infliximab; Merck & Co./Johnson & Johnson Innovative Medicine), Enbrel (etanercept; Amgen), Cimzia (certolizumab; UCB)
    • Key insights summary

Anti-IL17 drugs

  • Cosentyx (secukinumab; Novartis)
    • Key insights summary
  • Taltz (ixekizumab; Lilly)
    • Key insights summary
  • Siliq (US)/Kyntheum (EU)brodalumab; Ortho Dermatologics/LEO Pharma)
    • Key insights summary
  • Bimzelx (bimekizumab; UCB)
    • Key insights summary

Anti-IL12/23 drugs

  • Stelara (ustekinumab; Johnson & Johnson Innovative Medicine)
    • Key insights summary

Anti-IL23 drugs

  • Tremfya (guselkumab; Johnson & Johnson Innovative Medicine)
    • Key insights summary
  • Ilumya/Ilumetri (tildrakizumab; Sun Pharma/Almirall)
    • Key insights summary
  • Skyrizi (risankizumab; AbbVie)
    • Key insights summary

PDE IV antagonists

  • Otezla (apremilast; Amgen)
    • Key insights summary

Tyrosine Kinase 2 inhibitor

  • Sotyktu (deucravacitinib; Bristol Myers Squibb)
    • Key insights summary

Pipeline drugs

  • Piclidenoson (Can-Fite BioPharma)
    • Key insights summary
  • Zasocitinib (TAK 279; Takeda)
    • Key insights summary
  • JNJ 77242113 (Johnson & Johnson Innovative Medicine)
    • Key insights summary

Future outlook and treatment dynamics for management of psoriasis

  • Key insights summary
    • Risankizumab, guselkumab and bimekizumab will pose strong competition to other drugs within the psoriasis treatment paradigm: biosimilars will enable early intervention with biologics

Appendix

KOL Bulletins